Clinical Highlights

Learn More About Cervical Dystonia with Dr. Joseph Jankovic

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

Revance Announces Top-Line Results for ASPEN-1

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA.

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines

Dermatologic Surgery

• Author: Green, Jeremy B. MD et al.
• Published on August 6, 2020

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study

Dermatologic Surgery

• Author: Fabi, Sabrina G. MD et al.
• Published on August 6, 2020

Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds

Dermatologic Surgery

• Author: Gary Monheit, M.D.
• Published on March 24, 2020

DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)

Journal of the American Academy of Dermatology

• Author: Vince Bertucci, M.D. et al
• Published on December 2, 2019